Key result
Late bone marrow mononuclear cell injection fails to improve LV function in chronic ischemic scars.
Why the study?
Does intramyocardial injection of bone marrow mononuclear cells improve contractile function and attenuate left ventricular remodeling in mice with chronic myocardial infarct scars (8 weeks post-ischemia/reperfusion)?
Does intramyocardial injection of bone marrow mononuclear cells improve contractile function and attenuate left ventricular remodeling in mice with chronic myocardial infarct scars (8 weeks post-ischemia/reperfusion)?
Demonstrates a 'point of no return' in mature infarct scars where late intramyocardial bone marrow mononuclear cell therapy fails to improve cardiac function or alter fibrosis despite inducing local macrophage inflammation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Vagnozzi et al. (2021) studied Chronically scarred rodent heart (8 weeks post-ischemia/reperfusion injury). Intramyocardial injection of mTomato-labeled bone marrow mononuclear cells (MNCs) vs. Sterile saline intramyocardial injection was evaluated on Contractile function (fractional shortening, %FS) and left ventricular remodeling (end-systolic volume, LVESV) at 2 weeks post-injection.
Synapse has enriched 5 related papers. Consider them for comparative context: